1 / 10

Glecaprevir - Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3 ENDURANCE-3

Phase 3. Treatment-Naïve. Glecaprevir - Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3 ENDURANCE-3. Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69. Glecaprevir - Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3 ENDURANCE-3: Study Features.

canon
Download Presentation

Glecaprevir - Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3 ENDURANCE-3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve Glecaprevir-Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3ENDURANCE-3 Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  2. Glecaprevir-Pibrentasvir in Treatment-Naïve, Non-Cirrhotic GT 3ENDURANCE-3: Study Features Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  3. Glecaprevir-Pibrentasvir in Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3: Study Design 0 8 12 20 24 Week GLE-PIB GT-3 Naïve Non-cirrhotic n =233 SVR12 SOF + DCV n =115 SVR12 GLE-PIB n =157 SVR12 348 patients were randomized in 2:1 ratio to 12 weeks of GLE-PIB vs SOF + DCV. 157 were not randomized but assigned to 8 weeks of GLE-PIB. Abbreviations: GLE-PIB = glecaprevir-pibrentasvir; SOF = sofosbuvir; DCV = daclatasvir Drug DosingGlecaprevir-pibrentasvir: 300/120 mg once dailySofosbuvir 400 mgonce dailyplus Daclatasvir 60 mgonce daily Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  4. Glecaprevir-Pibrentasvirin Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3: Baseline Characteristics GLE-PIB= glecaprevir-pibrentasvir; SOF= sofosbuvir; DCV= daclatasvir; BMI = body mass index Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  5. Glecaprevir-Pibrentasvirin Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3 Study: Results ION-3: SVR 12 by Treatment Duration and Regimen (ITT Analysis) 111/115 149/157 222/233 12-Week Regimens 8-Week Regimen GLE-PIB = glecaprevir-pibrentasvir; SOF = sofosbuvir; DCV= daclatasvir ITT = Intent-to-treat Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  6. Glecaprevir-Pibrentasvirin Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3: Treatment Outcomes SVR = Sustained virologic response; GLE-PIB= glecaprevir-pibrentasvir; SOF= sofosbuvir; DCV= daclatasvir Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  7. Glecaprevir-Pibrentasvirin Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3: Resistance Analysis *Detected at 15% threshold by next-generation sequencing in samples that had sequences available at a key subset of amino acid positions: NS3: 36, 55, 56, 80, 155, 156, 166, 168; NS5A at 24, 28, 29, 30, 31, 32, 58, 92, 93 GLE-PIB= glecaprevir-pibrentasvir; SOF= sofosbuvir; DCV= daclatasvir Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  8. Glecaprevir-Pibrentasvirin Treatment-Naïve Non-Cirrhotic GT 3ENDURANCE-3: Adverse Events Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  9. Glecaprevir-Pibrentasvir for 8 or 12 weeks in Non-Cirrhotic GT 1*ENDURANCE-3: Conclusions *Note: ENDURANCE-3 was published in conjunction with ENDURANCE-1 Source: Zeuzem S, et al. N Engl J Med. 2018;378:354-69.

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related